** Exact Sciences EXAS.O falls 10% to $42.20 after blood colorectal cancer $(CRC)$ test did not meet expectations in trial
** Brokerage BTIG calls it a "worst case scenario"
** This also overshadowed a strong beat and raise Q2
** EXAS on Weds inked deal for exclusive rights to Freenome's blood-based screening CRC test, but analysts noted this excluded multi-cancer tests, which disappointed investors
** At least six brokerages cut price targets
** Shares of rival Guardant Health GH.O gain nearly 17%
** Canaccord Genuity says GH's Shield test performance is a touch better than Freenome's test
** EXAS stock down 27% YTD while GH has surged nearly 70%
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。